Skip to main content
. 2022 Jan 4;13(1):1411–1423. doi: 10.1080/21655979.2021.2018096

Figure 1.

Figure 1.

Upregulation of circZNF652 in GBM tissues and cell lines, and associates with aggravate progression in GBM. (a) and (b) The expression of circZNF652 in GBM tissues, adjacent normal tissues, I-II clinical stage, III-IV clinical stage. (c) The overall survival curve of high and low circZNF652 expression GBM patients. (d) The expression of circZNF652 in NHA, A172, U251, LN229, U87 cells. ***P < 0.001.